Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2005
07/26/2005CA2133439C Compounds useful for treating allergic and inflammatory diseases
07/26/2005CA2112011C Substituted pyridines
07/22/2005CA2455659A1 Barhl2 proteins, genes encoding the same and uses thereof
07/21/2005WO2005066371A2 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
07/21/2005WO2005066330A1 A system for improving acceptance of tissue grafts made from embryonic stem cells
07/21/2005WO2005066215A1 Cohesive gels form cross-linked hyaluronan and/or hylan, their preparation and use
07/21/2005WO2005066214A1 Hyaluronic acid derivative and drug containing the same
07/21/2005WO2005066197A2 Inhibitors of methionine aminopeptidase-2 and uses thereof
07/21/2005WO2005066196A1 Amorphous form of finasteride and processes for its preparation
07/21/2005WO2005066194A1 Helix 12 directed steroidal pharmaceutical products
07/21/2005WO2005066190A1 New risedronate salts
07/21/2005WO2005066189A1 Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
07/21/2005WO2005066181A1 Process for the preparation of 1,3-dioxolo [4,5-c] piperidin-7-ols and related compounds
07/21/2005WO2005066178A1 Triaza-cyclopenta[cd]indene derivatives
07/21/2005WO2005066177A1 Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
07/21/2005WO2005066176A1 Pyrrolotriazine compounds as kinase inhibitors
07/21/2005WO2005066172A1 Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
07/21/2005WO2005066171A1 Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
07/21/2005WO2005066168A1 Spirocyclic quinuclidinic ether derivatives
07/21/2005WO2005066167A2 3-quinuclidinyl heteroatom bridged biaryl derivatives
07/21/2005WO2005066166A2 3-quinuclidinyl amino-substituted biaryl derivatives
07/21/2005WO2005066163A2 Thiophene derivatives as chk 1 inihibitors
07/21/2005WO2005066160A1 Dutpase inhibitors
07/21/2005WO2005066159A1 Cathepsin cysteine protease inhibitors
07/21/2005WO2005066156A1 Selective kinase inhibitors
07/21/2005WO2005066151A2 Histone deacetylase inhibitors
07/21/2005WO2005066148A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
07/21/2005WO2005066145A1 Heteroaryl-ureas and their use as glucokinase activators
07/21/2005WO2005066143A2 Benzo[d]isoxazol-3-ol daao inhibitors
07/21/2005WO2005066137A1 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases
07/21/2005WO2005066135A2 Pyrrole and pyrazole daao inhibitors
07/21/2005WO2005066132A1 Therapeutic agents i
07/21/2005WO2005066129A2 Bis-pyridino containing compounds for use in the treatment of cns pathologies
07/21/2005WO2005066123A1 Protease inhibitors
07/21/2005WO2005066116A1 Disubstituted chalcone oximes as selective agonists of rarϝ retinoid receptors
07/21/2005WO2005066115A2 Disubstituted chalcone oximes having rarϝ retinoid receptor antagonist activity
07/21/2005WO2005066114A1 Compounds for diagnosis, treatment and prevention of bone injury and metabolic disorders
07/21/2005WO2005065779A1 Calcitonin gene related peptide receptor antagonists
07/21/2005WO2005065726A1 Pharmaceutical composition
07/21/2005WO2005065722A2 Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
07/21/2005WO2005065721A2 Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex
07/21/2005WO2005065719A1 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
07/21/2005WO2005065718A2 Antitumour treatments with metxia-p450 and cyclophosphamide or 5t4 vaccine
07/21/2005WO2005065713A2 Topically applied medicament for animals
07/21/2005WO2005065712A2 Complexes having adjuvant activity
07/21/2005WO2005065706A1 Pharmaceutical composition for thrombin peptide derivatives
07/21/2005WO2005065696A1 Pharmaceutical compositions comprising an extract of euphorbia prostrata
07/21/2005WO2005065695A1 Method and formula for suppression of cancer, metastasis, vascularization, and pain suppression
07/21/2005WO2005065694A1 Therapeutic composition for the treatment of human eye accommodation disorders
07/21/2005WO2005065692A1 Treatment
07/21/2005WO2005065691A1 Treatment of malignant gliomas with tgf-beta inhibitors
07/21/2005WO2005065690A1 Treatment of hepatic fibrosis with imatinib mesylate
07/21/2005WO2005065689A1 Dutpase inhibitors
07/21/2005WO2005065687A1 Novel pharmaceutical combinations containing scopine or tropic acid esters and egfr-kinase inhibitors
07/21/2005WO2005065686A1 Differentiation modulating agents and uses therefor
07/21/2005WO2005065685A1 Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
07/21/2005WO2005065684A1 Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
07/21/2005WO2005065683A1 Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes
07/21/2005WO2005065682A2 Rabeprazole containing formulation
07/21/2005WO2005065681A1 N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
07/21/2005WO2005065680A1 Cyclic guanidines, compositions containing such compounds and methods of use
07/21/2005WO2005065679A1 Isoflavone therapy for treating urinary incontinence
07/21/2005WO2005065678A1 Immunomodulatory combinations
07/21/2005WO2005065677A1 Fat emulsion for dissolving or dispersing paclitaxel or docetaxel
07/21/2005WO2005065676A1 Fat emulsion containing paclitaxel or docetaxel
07/21/2005WO2005065675A1 Method of treatment
07/21/2005WO2005065674A1 Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
07/21/2005WO2005065673A1 Atomoxetine formulations
07/21/2005WO2005065672A1 Antiaging composition
07/21/2005WO2005065671A1 Preventive for the onset of liver cancer comprising quinone compound as the active ingredient
07/21/2005WO2005065670A1 Use of idebenone for the preparation of a topically-applied depigmentation composition and corresponding composition
07/21/2005WO2005065669A1 Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
07/21/2005WO2005065668A2 Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
07/21/2005WO2005065667A2 Compositions for treating or preventing obesity and insulin resistance disorders
07/21/2005WO2005065666A1 Us of a pkc-delta inhibitor for the inhibition of metastatic melanoma
07/21/2005WO2005065665A2 Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
07/21/2005WO2005065664A1 Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
07/21/2005WO2005065663A1 Rosiglitazone and metformin formulations
07/21/2005WO2005065662A1 Solid dosage formulations of galantamine
07/21/2005WO2005065661A2 Immediate, controlled and sustained release formulations of galanthamine
07/21/2005WO2005065660A2 Ziprasidone formulations
07/21/2005WO2005065655A2 Method for producing keto-l-gulonic acid spray granules
07/21/2005WO2005065654A2 Rosiglitazone formulations
07/21/2005WO2005065653A1 Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
07/21/2005WO2005065651A1 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
07/21/2005WO2005065649A1 Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid
07/21/2005WO2005065648A2 Novel drug compositions and dosage forms of topiramate
07/21/2005WO2005065646A2 Novel drug compositions and dosage forms
07/21/2005WO2005065645A2 Donepezil formulations
07/21/2005WO2005065641A2 Non-disintegrating oral solid composition of high dose of water soluble drugs
07/21/2005WO2005065640A1 Compositions of buccal dosage forms for extended drug release and the process of preparing such compositions
07/21/2005WO2005065639A2 Novel pharmaceutical compositions
07/21/2005WO2005065551A2 Treatment of skin using a benefit agent and an apparatus
07/21/2005WO2005065455A1 Immunomodulatory compounds for the treatment of central nervous system disorders
07/21/2005WO2005065435A2 Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
07/21/2005WO2005065429A2 Composition and method for treatment of hepatic encephalopathy
07/21/2005WO2005065405A1 Membranes incorporating recognition moieties
07/21/2005WO2005065372A2 Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
07/21/2005WO2005065361A2 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
07/21/2005WO2005065319A2 Generally linear effervescent oral fentanyl dosage form and methods of administering
1 ... 4605 4606 4607 4608 4609 4610 4611 4612 4613 4614 4615 4616 4617 4618 4619 4620 4621 4622 4623 4624 4625 ... 7860